Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
NJ's Horizon BCBS Pays $3M in Shared Savings for Episodes of Care; Readmissions, C-Sections Reduced
February 18th 2016The shared savings payments were for specialists in hip and knee replacements, knee arthroscopy, and pregnancy. These areas have been among CMS' top targets for savings, while New Jersey has been focused on reducing its high rate of C-sections.
Read More
South Carolina to Spend $30M to Cut Infant Mortality Using Value-Based Principles
February 17th 2016The Nurse-Family Partnership expansion will bring 3200 new families into the program over 4 years. The nonprofit initiative is backed by 30 years of evidence, including a 2014 study that showed better long-term survival among 20-year-olds whose mothers were among the early participants.
Read More
Michigan Governor Wants Medicaid Benefits for Flint Water Crisis
February 15th 2016The requested Medicaid waiver from CMS would help deal with the Flint water crisis. Residents have been affected by lead poisoning after a state-hired emergency manager switched the city's water supply from Lake Huron to the Flint River, without following advice for pretreating the water.
Read More
Data Show Diabetics Using Verapamil Have Lower Glucose Levels
February 12th 2016The results amplify earlier work at UAB that showed verapamil reversed type 1 diabetes in mice. A clinical trial involving the drug in recently diagnosed patients with type 1 disease is still enrolling participants.
Read More
Life-Saving Insulin Too Costly for Many of the World's Type 1 Diabetics, Lancet Review Finds
February 6th 2016The authors note that not only are insulin costs making type 1 diabetes deadly in the poorest nations; high costs are the leading reason for diabetic ketoacidosis in the inner cities in the United States.
Read More